Skip to content

Released Aug 8, 2024, before the open

10-Q filed Aug 8, 2024, 39 days after period end · 0001628280-24-035893

Q2 2024 · 10-Q
Revenue$0.00— vs Q2 2023−100.0% vs Q1 2024
Net Income-$55.33MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.46N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$55,672,000N/M
Operating Cash Flowderived-$45,491,000N/M
Free Cash Flowderived-$47,393,000N/M

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Revenue$0.00$0.00——
Net Income-$55.33M-$42.39M-$29.35M$616.00K
EPS Diluted-$0.46-$0.47-$1.76—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR